{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:47:06Z","timestamp":1787006826570,"version":"build-2736575974"},"reference-count":38,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2026,2,23]]},"DOI":"10.1080\/10428194.2025.2604300","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:50:03Z","timestamp":1768845003000},"page":"627-637","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017\u20132024)"],"prefix":"10.1080","volume":"67","author":[{"given":"Tycel","family":"Phillips","sequence":"first","affiliation":[{"name":"City of Hope Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Genesis Research Group","place":["Hoboken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Genesis Research Group","place":["Hoboken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Shao","sequence":"additional","affiliation":[{"name":"Genesis Research Group","place":["Hoboken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marley","family":"Boyd","sequence":"additional","affiliation":[{"name":"Genesis Research Group","place":["Hoboken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Noshad","sequence":"additional","affiliation":[{"name":"Genesis Research Group","place":["Hoboken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriana","family":"Hohlbauch","sequence":"additional","affiliation":[{"name":"Genesis Research Group","place":["Hoboken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Repetny","sequence":"additional","affiliation":[{"name":"Pfizer","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Pfizer","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Pfizer","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anne","family":"Davis","sequence":"additional","affiliation":[{"name":"Cencora, Conshohocken","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Gennarelli","sequence":"additional","affiliation":[{"name":"Cencora, Conshohocken","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute and Rocky Mountain Cancer Centers","place":["Aurora, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25460"},{"key":"e_1_3_5_3_1","unstructured":"National Cancer Institute. SEER cancer stat facts: Diffuse large B-cell lymphoma: [cited 2024 August 21]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.366"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0650-x"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101140"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010070"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02087-4"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1957806"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0788"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0191"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7173"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02242"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac256"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188771"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002395"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204255"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209252"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180109"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7581"},{"key":"e_1_3_5_30_1","unstructured":"US Food and Drug Administration. FDA approves axicabtagene ciloleucel for large B-cell lymphoma; 2017 [updated October 25 2017; cited 2025 October 21]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162730"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0094"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13721"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203238"},{"key":"#cr-split#-e_1_3_5_35_1.1","unstructured":"US Food and Drug Administration. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma: 2022 [updated April 1 2022"},{"key":"#cr-split#-e_1_3_5_35_1.2","unstructured":"cited 2025 October 21]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma."},{"key":"e_1_3_5_36_1","unstructured":"US Food and Drug Administration. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma; 2019 [updated June 10 2019; cited 2025 October 21]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma."},{"key":"e_1_3_5_37_1","unstructured":"US Food and Drug Administration. FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma not otherwise specified and high-grade B-cell lymphoma; 2023 [updated April 19 2023; cited 2025 October 21]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-previously-untreated-diffuse-large-b-cell-lymphoma-not."},{"key":"e_1_3_5_38_1","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma; 2023 [updated May 19 2023; cited 2025 October 21]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell."}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2604300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:41:58Z","timestamp":1773117718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2604300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,23]]}},"alternative-id":["10.1080\/10428194.2025.2604300"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2604300","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}